## **Supplementary Information:**

High density lipoprotein (HDL) particles from end-stage renal disease patients are defective in promoting reverse cholesterol transport

Josephine L.C. Anderson<sup>1</sup>, Thomas Gautier<sup>2</sup>, Niels Nijstad<sup>1</sup>, Markus Toelle<sup>3</sup>, Mirjam Schuchardt<sup>3</sup>, Markus van der Giet<sup>3</sup>, and Uwe J.F. Tietge<sup>1</sup>

<sup>&</sup>lt;sup>1</sup> Department of Pediatrics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

<sup>&</sup>lt;sup>2</sup> INSERM UMR866 Lipides, Nutrition, Cancer; Faculté de Médecine, Dijon, France

<sup>&</sup>lt;sup>3</sup> Medizinische Klinik IV – Nephrology, Charite – Campus Benjamin Franklin, Berlin, Germany

Supplemental Table S1: Clinical and biochemical characteristics of the end-stage renal disease (ESRD) patients and controls investigated

	ESRD (n=15)	Controls (n=15)	P value
Age (years)	48 (31-56)	46 (26-64)	n.s.
Sex (male/female)	10/5	9/6	n.s.
Body weight (kg)	74 (56-83)	69 (59-90)	n.s.
Duration of dialysis (months)	38 (24-78)	0	
Serum creatinine (mg/dl)	7.1 (5.4-9.4)	1.0 (0.7-1.2)	< 0.001
Blood urea nitrogen (mg/dl)	26 (22-38)	14 (10-16)	< 0.001
Total protein (g/l)	64 (50-81)	69 (67-73)	n.s.
Cholesterol (mg/dl)	251 (184-283)	180 (166-214)	< 0.05
CRP (mg/l)	5.8 (2.0-8.5)	1.1 (0.7-1.5)	< 0.001
Smoking	3 (20)	0 (0)	< 0.01
Diabetes	6 (40)	0 (0)	< 0.001
Coronary heart disease	6 (40)	0 (0)	< 0.001
Lipid lowering drugs	9 (60)	0 (0)	< 0.001

Data are presented as median (range) or total numbers (%).


Supplemental Table S2: Mass composition of HDL isolated from ESRD patients and controls


	controls (n=15)	ESRD (n=13)
Cholesterol ester (%)	$14.1 \pm 0.3$	$11.3 \pm 0.9$ §
Free cholesterol (%)	$4.5 \pm 0.1$	$4.8\pm0.1^{\S}$
Phospholipids (%)	$14.5 \pm 0.6$	$13.7 \pm 0.7$
Triglycerides (%)	$2.8 \pm 0.1$	$5.2\pm0.5^{\S}$
Protein (%)	$64.2 \pm 0.7$	$65.0 \pm 1.1$

Values are means  $\pm$  SEM.

Significantly different from controls:  $^{\$}$  at least p<0.05.

## **Supplemental figure S1**





Supplemental figure S1: ESRD-HDL displays defective cholesterol uptake as well as cholesterol delivery properties. (a) Cholesterol efflux from primary mouse peritoneal macrophages towards HDL and (b) Cellular SR-BI mediated selective cholesterol uptake form HDL. In these experioments HDL was used isolated either from healthy controls subjects (control, n=15), ESRD-patients without additional risk factors (ESRD, n=5) and ESRD patients with at least one of the additional risk factors smoking, diabetes and lipid lowering medication (ESRD + risk factors, n=10). Data are presented as means  $\pm$  SEM. \*p<0.05, \*\*\*p<0.001